Cancer BiologybioRxivPreprint
Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin
Chiara Facciotto, Julia Casado, Laura Turunen…·Sampsa Hautaniemi
This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.
DOI 10.1101/538199